SNPX - Synaptogenix, Inc.
2.3605
-0.075 -3.186%
Share volume: 1,971
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$2.44
-0.08
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-15-2024 | 08-14-2024 | 11-12-2024 | 03-27-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||
| Operating expenses | 1.691 M | 1.581 M | 1.360 M | 2.179 M | |
| Selling general and admin | 1.082 M | 1.239 M | 1.137 M | 1.754 M | |
| Research and development | 609.249 K | 342.068 K | 222.897 K | 424.508 K | |
| Total expenses | 1.691 M | 1.581 M | 1.360 M | 2.179 M | |
| -6.53% | -14.00% | 60.23% | |||
| Operating income | -1.691 M | -1.581 M | -1.360 M | -2.179 M | |
| Ebit | -661.494 K | -1.594 M | -6.031 M | -5.196 M | |
| Pretax income | -206.699 K | -1.273 M | -5.742 M | -5.547 M | |
| 516.02% | 350.95% | -3.40% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -206.699 K | -1.273 M | -5.742 M | -5.547 M | |
| -516.02% | -350.95% | 3.40% |
